Atebimetinib
Sponsors
Immuneering Corp., Immuneering Corporation
Conditions
Metastatic Pancreatic Ductal AdenocarcinomaPDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic AdenocarcinomaPancreatic Adenocarcinoma MetastaticPancreatic CancerPancreatic Cancer MetastaticPancreatic Ductal Adenocarcinoma
Phase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingNCT07562152
Start: 2026-06-05End: 2029-02-01Target: 510Updated: 2026-09-18
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
Not yet recruitingCTIS2026-525617-31-00
Target: 225Updated: 2026-09-18